Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2019 Apr 2;11:291-300. doi: 10.1016/j.dadm.2019.02.002. eCollection 2019 Dec.

Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers.

Author information

1
Research and Development, Roche Diagnostics GmbH, Penzberg, Germany.
2
gRED OMNI-BD, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
3
Medical and Scientific Affairs, Roche Diagnostics International Ltd, Rotkreuz, Switzerland.

Abstract

Introduction:

We examined the influence of common preanalytical factors on the measurement of Alzheimer's disease-specific biomarkers in human plasma.

Methods:

Amyloid β peptides (Aβ[1-40], Aβ[1-42]) and total Tau plasma concentrations were quantified using fully automated Roche Elecsys assays.

Results:

Aβ(1-40), Aβ(1-42), and total Tau plasma concentrations were not affected by up to three freeze/thaw cycles, up to five tube transfers, the collection tube material, or the size; circadian rhythm had a minor effect. All three biomarkers were influenced by the anticoagulant used, particularly total Tau. Aβ concentrations began decreasing 1 hour after blood draw/before centrifugation and decreased by up to 5% and 10% at 2 and 6 hours, respectively. For separated plasma, time to measurement influenced Aβ levels by up to 7% after 6 hours and 10% after 24 hours.

Discussion:

Our findings provide guidance for standardizing blood sample collection, handling, and storage to ensure reliable analysis of Alzheimer's disease plasma biomarkers in routine practice and clinical trials.

KEYWORDS:

AD; Alzheimer's disease; Alzheimer's disease-specific biomarkers; Amyloid; Biomarkers; Elecsys immunoassay; Fully automated; Plasma; Preanalytics; Sample handling; Tau

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center